A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF TWO LENALIDOMIDE DOSE REGIMENS IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA.

Trial Profile

A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF TWO LENALIDOMIDE DOSE REGIMENS IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 02 May 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Allopurinol; Prednisone
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 01 May 2016 Status changed from recruiting to completed.
    • 03 May 2013 The Celgene ID for this study (CC5013-CLL001) is also in another profile (700020760). Have left it in both profiles for now as it is not clear which one is accurate.
    • 03 Jul 2012 Actual initiation date changed from 19 Apr 2007 to 23 Feb 2007 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top